Merck Phase 2b/3 Trial for Remigromig Meets Primary Endpoint

By Chris WackMerck said it saw positive topline results for its Phase 2b/3 trial for remigromig in adults with diabetic macular edema.The pharmaceutical company said the trial, the first of two Phase 2b/3 trials evaluating the safety and efficacy of remigromig met its primary endpoint.Remigromig is…